

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2017 Navy **Date:** February 2016

Appropriation/Budget Activity 1319: <i>Research, Development, Test & Evaluation, Navy / BA 5: System Development & Demonstration (SDD)</i>	R-1 Program Element (Number/Name) PE 0604771N / <i>Medical Development</i>
--	--

COST (\$ in Millions)	Prior Years	FY 2015	FY 2016	FY 2017 Base	FY 2017 OCO	FY 2017 Total	FY 2018	FY 2019	FY 2020	FY 2021	Cost To Complete	Total Cost
Total Program Element	99.660	26.589	25.291	9.220	-	9.220	9.313	9.570	9.776	9.968	Continuing	Continuing
0933: <i>Medical/Dental Equipment Dev</i>	16.884	8.089	9.291	9.220	-	9.220	9.313	9.570	9.776	9.968	Continuing	Continuing
9999: <i>Congressional Adds</i>	82.776	18.500	16.000	0.000	-	0.000	0.000	0.000	0.000	0.000	0.000	117.276

A. Mission Description and Budget Item Justification

The purpose of this item is to develop biomedical equipment and related techniques to reduce morbidity; to enhance the logistic feasibility of modern medical care for combat casualties; to sustain casualties for evacuation to fixed medical facilities for definitive care; and to ensure that personnel are medically qualified for military duty. Each work unit undertaken in this project has a military requirement. Efforts are justified based upon military payoff and cost benefit. There is a strong potential for dual use, technology transfer, and biotechnology firm/industry participation in the projects.

B. Program Change Summary (\$ in Millions)

	<u>FY 2015</u>	<u>FY 2016</u>	<u>FY 2017 Base</u>	<u>FY 2017 OCO</u>	<u>FY 2017 Total</u>
Previous President's Budget	27.287	9.443	9.599	-	9.599
Current President's Budget	26.589	25.291	9.220	-	9.220
Total Adjustments	-0.698	15.848	-0.379	-	-0.379
• Congressional General Reductions	-	-			
• Congressional Directed Reductions	-	-0.152			
• Congressional Rescissions	-	-			
• Congressional Adds	-	16.000			
• Congressional Directed Transfers	-	-			
• Reprogrammings	-	-			
• SBIR/STTR Transfer	-0.698	0.000			
• Rate/Misc Adjustments	0.000	0.000	-0.379	-	-0.379

Congressional Add Details (\$ in Millions, and Includes General Reductions)

Project: 9999: *Congressional Adds*

Congressional Add: *Military Dental Research*

Congressional Add: *Wound Care Research (transferred from Defense Health Program)*

Congressional Add Subtotals for Project: 9999

Congressional Add Totals for all Projects

	FY 2015	FY 2016
	5.895	6.000
	12.605	10.000
	18.500	16.000
	18.500	16.000

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2017 Navy **Date:** February 2016

Appropriation/Budget Activity
1319: *Research, Development, Test & Evaluation, Navy / BA 5: System Development & Demonstration (SDD)*

R-1 Program Element (Number/Name)
PE 0604771N / *Medical Development*

Change Summary Explanation

The FY 2017 funding request was reduced by -\$0.278 million as required for the Department of the Navy to comply with the Bipartisan Budget Act of 2015.

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2017 Navy										Date: February 2016		
Appropriation/Budget Activity 1319 / 5					R-1 Program Element (Number/Name) PE 0604771N / <i>Medical Development</i>				Project (Number/Name) 0933 / <i>Medical/Dental Equipment Dev</i>			
COST (\$ in Millions)	Prior Years	FY 2015	FY 2016	FY 2017 Base	FY 2017 OCO	FY 2017 Total	FY 2018	FY 2019	FY 2020	FY 2021	Cost To Complete	Total Cost
0933: <i>Medical/Dental Equipment Dev</i>	16.884	8.089	9.291	9.220	-	9.220	9.313	9.570	9.776	9.968	Continuing	Continuing
Quantity of RDT&E Articles		-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

The purpose of this budget item is to develop biomedical equipment and related techniques to reduce morbidity; to enhance the logistic feasibility of modern medical care for combat casualties; to sustain casualties for evacuation to fixed medical facilities for definitive care; and to ensure that personnel are medically qualified for military duty. Each work unit undertaken in this project has a military requirement. Efforts are justified based upon military payoff and cost benefit. There is a strong potential for dual use, technology transfer, and biotechnology firms/industry participation in the projects.

B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)

	FY 2015	FY 2016	FY 2017 Base	FY 2017 OCO	FY 2017 Total
Title: Medical/Dental Equipment Dev	8.089	9.291	9.220	0.000	9.220
Articles:	-	-	-	-	-
FY 2015 Accomplishments:					
-Continued to augment efforts with the ongoing clinical trial effort to test, for safety and efficacy, a militarily relevant malaria vaccine regimen utilizing a promising vaccine candidate. Initiated cellular immunity studies on FDA Phase 1 clinical trial samples.					
-Continued utilization validation of Individual Fatigue-Based Scheduling and Countermeasure System that predicts, prevents, detects, and mitigates periods of high risk associated with fatigue. Transitioned schedule based crew qualification logic for incorporation into the graphical user interface.					
-Continued controlled efficacy study of an intradermal vaccine to an experimental challenge of model of Enterotoxigenic Escherichia coli (ETEC). Initiated third clinical trial cohort.					
-Continued transition projects from the Force Health Protection Future Naval Capability Program (FNC). Product focus is management of casualties during the extended distances and times required to support the Naval Expeditionary Health Services. Major efforts to include cerebral perfusion pressure and hemorrhage control (including Multifunctional Resuscitation Fluid).					
-Continued to validate the quality control analysis of shelf life extension and bioavailability of intranasal scopolamine for the prevention of motion sickness in dynamic military environments. Presented intranasal scopolamine nasal gel motion sickness trial results at FDA meeting.					
-Continued joint development projects with MARCORSSYSCOM acquisition including developing Mobile Oxygen Ventilation and External Suction (MOVES) SLC development, to include new test and evaluation following improved ruggedization.					

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2017 Navy		Date: February 2016
Appropriation/Budget Activity 1319 / 5	R-1 Program Element (Number/Name) PE 0604771N / <i>Medical Development</i>	Project (Number/Name) 0933 / <i>Medical/Dental Equipment Dev</i>

B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)

	FY 2015	FY 2016	FY 2017 Base	FY 2017 OCO	FY 2017 Total
<p>-Initiated Naval Expeditionary Health Service Support: Shore based capabilities based military treatment facility.</p> <p>-Completed validation of computer color vision test (CCVT) for use in Naval Aviation. Chief of Naval Air Forces recommended to BUMED that CCVT test be incorporated into NAVMED P-117.</p> <p>FY 2016 Plans:</p> <p>-Continue support of ongoing clinical trial effort to test, for safety and efficacy, a militarily relevant malaria vaccine regimen utilizing a promising vaccine candidate. Initiate validation of Good Manufacturing Practices (GMP) support for vaccine production scale up.</p> <p>-Continue field user evaluation and validation of Individual Fatigue-Based Scheduling and Countermeasure System that predicts, detects, and prevents or mitigates fatigue during periods of high risk. Individualized performance risk will be predicted and prevented by providing individual fatigue optimized schedules and mitigation strategies for the operating forces.</p> <p>-Continue controlled efficacy study of an intradermal vaccine to an experimental challenge model of Enterotoxigenic Escherichia coli (ETEC). Complete analysis of third clinical trial cohort.</p> <p>-Continue development of transitioned FNC products for cerebral perfusion pressure management and massive hemorrhage control.</p> <p>-Continue stability studies to validate the quality control analysis of shelf life extension and bioavailability of intranasal scopolamine for the prevention of motion sickness in dynamic military environments.</p> <p>-Continue Naval Expeditionary Health Service Support. Primary focus includes: 1) support of shore based and afloat Capabilities-Based Military Treatment Facility consistent with medical mission module evolving concepts; 2) Enhancing casualty treatment capabilities while reducing the overall logistics burden.</p> <p>-Continue joint development projects with MARCORSSYSCOM acquisition for medical products and equipment.</p> <p>FY 2017 Base Plans:</p> <p>-Continue to augment efforts with the ongoing clinical trial effort to test, for safety and efficacy, a militarily relevant malaria vaccine regimen utilizing a promising vaccine candidate. Continue with validation of manufacturing support for vaccine production scale up.</p> <p>-Continue utilization validation of Individual Fatigue-Based Scheduling and Countermeasure System that predicts, prevents, detects, and mitigates periods of high risk associated with fatigue. Individualized performance risk will be predicted and prevented by providing individual fatigue optimized schedules and mitigation strategies.</p> <p>-Continue development of transitioned FNC products and technologies for cerebral perfusion pressure and hemorrhage control.</p> <p>-Complete primary investment to validate the quality control analysis of shelf life extension and bioavailability of intranasal scopolamine for the prevention of motion sickness in dynamic military environments.</p>					

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2017 Navy	Date: February 2016
--	----------------------------

Appropriation/Budget Activity 1319 / 5	R-1 Program Element (Number/Name) PE 0604771N / <i>Medical Development</i>	Project (Number/Name) 0933 / <i>Medical/Dental Equipment Dev</i>
--	--	--

B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)	FY 2015	FY 2016	FY 2017 Base	FY 2017 OCO	FY 2017 Total
-Continue Naval Expeditionary Health Service Support efforts. Primary focus includes: 1) Completion of the extended distances and time considerations; and 2) Continue en route care, patient transport and trauma care systems associated with the time distance continuum in a sea base environment. -Continue joint development projects with MARCORSSYSCOM acquisition for medical products and equipment. FY 2017 OCO Plans: N/A					
Accomplishments/Planned Programs Subtotals	8.089	9.291	9.220	0.000	9.220

C. Other Program Funding Summary (\$ in Millions)

N/A

Remarks

D. Acquisition Strategy

The acquisition strategy for product lines and products in the Medical Development Program is designed and implemented consistent with the purpose of the particular product and with the nature and size of the investment. The Medical Development Program has a Memorandum of Agreement with the Marine Corps Systems Command (Family of Field Medical Equipment) for co-development of products for procurement by the USMC. The acquisition strategy for products involves direct partnership with the acquisition and procurement professionals at Marine Corps Systems Command.

The major Product Areas in the Medical Development Program are: 1) Equipment, 2) Pharmaceuticals/Biologics, and 3) Operational Knowledge/Concepts. The primary Program Areas of Interest are in: 1) Naval Expeditionary Health Services Support (Navy in Terrestrial, Maritime Surface, Submarine, & Aviation Operations), 2) USMC in Expeditionary Operations and 3) Products for battlefield treatment and en route care of Combat Casualties & Combat Trauma, focusing on delivery of care within the seabase and the littoral environment.

For Product Areas 1 and 2, there are two primary acquisition strategies. The first is to test and evaluate for Naval application commercially-developed medical product or candidates in managed trials with the ultimate goal of Food and Drug Administration (FDA) approval. Partnerships with commercial developers promotes developing products of military interest for procurement by the Operating Forces. A second benefit of this strategy is that products are made available across the DoD, Federal Government, and commercial market, thus reducing overall procurement costs. During development, DoD end users are included in the process to the extent possible. The second strategy is to drive a collaborative development process with larger DoD program investments. Navy and Marine Corps needs can be met at lower service cost. This process involves developing in-house or industrial prototypes in government-managed programs to meet Naval needs while meeting regulatory requirements for production and fielding. Both tactics promote development of procurement plans that align product availability with Service integration strategies.

The Third Product Area (Knowledge/Concepts) is focused on the introduction of technologies, techniques, and procedures that enhance medical practice and standards of care for effective delivery of health care and casualty care in the Naval operating environment. These primarily require early involvement of the senior leadership

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2017 Navy Date: February 2016

Appropriation/Budget Activity	R-1 Program Element (Number/Name)	Project (Number/Name)
1319 / 5	PE 0604771N / <i>Medical Development</i>	0933 / <i>Medical/Dental Equipment Dev</i>

of military medicine, in that the end product of the program is modification of concepts of operations, policy, and/or doctrine. While these are often much smaller investments, they can have a substantial impact on the care of Sailors and Marines; Medical Development Program examples include Navy/USMC Medical Planning Requirement Assessment and Color Vision Screening Validation.

E. Performance Metrics

Successful completion of Milestones/Demonstration Events for individualized project/product roadmap, on time and on budget. Ensuring dependencies across multiple efforts are maintained on schedule are primary metrics.

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2017 Navy **Date:** February 2016

Appropriation/Budget Activity 1319 / 5	R-1 Program Element (Number/Name) PE 0604771N / <i>Medical Development</i>	Project (Number/Name) 0933 / <i>Medical/Dental Equipment Dev</i>
--	--	--

Product Development (\$ in Millions)				FY 2015		FY 2016		FY 2017 Base		FY 2017 OCO		FY 2017 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Malaria Vaccine	SS/CR	Sanaria, Inc. : Rockville, MD	0.000	2.000	Aug 2015	1.500	Aug 2016	0.785	Aug 2017	-		0.785	Continuing	Continuing	Continuing
Malaria Vaccine	Allot	Naval Medical Research Center : Silver Spring, MD	0.840	0.432	Mar 2015	0.350	Mar 2016	0.210	Mar 2017	-		0.210	Continuing	Continuing	Continuing
Malaria Vaccine	C/FFP	Evolution Enterprises : San Diego, CA	0.000	0.060	Aug 2015	0.045	Aug 2016	0.023	Aug 2017	-		0.023	0.000	0.128	-
Individualized Fatigue Based Scheduling	SS/FP	Pulsar Informatics : Philadelphia, PA	4.165	0.556	Jun 2015	1.089	Jun 2016	0.537	Jun 2017	-		0.537	Continuing	Continuing	Continuing
Human Factors Individualized Fatigue Based Scheduling	Allot	Naval Submarine Medical Research Laboratory : Groton, CT	0.737	0.394	Nov 2014	0.400	Nov 2015	0.250	Nov 2016	-		0.250	Continuing	Continuing	Continuing
Fatigue Based Scheduling	Allot	Naval Post Graduate School : Monterey, CA	0.511	0.221	Jun 2015	0.216	Nov 2015	0.190	Dec 2016	-		0.190	Continuing	Continuing	Continuing
Management of Cerebral Perfusion Pressure	SS/FP	University of Miami : Miami, FL	0.400	0.361	Apr 2015	0.761	Apr 2016	0.761	Apr 2017	-		0.761	Continuing	Continuing	Continuing
Naval Expeditionary Health Service Support: Capability Based Military Treatment Facility Evaluation	WR	Navy Expeditionary Medical Support Command : Williamsburg, VA	0.000	0.363	May 2015	0.000		0.000		-		0.000	0.363	0.726	-
Naval Expeditionary Health Service Support: Capability Based Military Treatment Facility Energy Efficiency	TBD	TBD : Not Specified	0.000	0.000		1.000	Aug 2016	2.600	Aug 2017	-		2.600	3.600	7.200	-
Multifunctional Resuscitation	Allot	Naval Medical Research Unit - San Antonio : San Antonio, TX	0.000	1.200	Feb 2015	0.582	Feb 2016	0.385	Feb 2017	-		0.385	Continuing	Continuing	Continuing
BioSurveillance Information	MIPR	Pacific Disaster Center : Kihei, HI	0.634	0.095	May 2015	0.050	Dec 2015	0.000		-		0.000	0.779	1.558	-

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2017 Navy **Date:** February 2016

Appropriation/Budget Activity 1319 / 5	R-1 Program Element (Number/Name) PE 0604771N / <i>Medical Development</i>	Project (Number/Name) 0933 / <i>Medical/Dental Equipment Dev</i>
--	--	--

Product Development (\$ in Millions)				FY 2015		FY 2016		FY 2017 Base		FY 2017 OCO		FY 2017 Total	Cost To Complete	Total Cost	Target Value of Contract
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost			
ETEC Vaccine	Allot	Naval Medical Research Center : Silver Spring, MD	0.359	0.727	Feb 2015	0.000		0.000		-		0.000	1.086	2.172	-
Novel Ossointegration Device	Allot	Naval Medical Research Center : Silver Spring, MD	0.498	0.273	Feb 2015	0.277	Feb 2016	0.000		-		0.000	1.048	2.096	-
Intranasal Scopolamine Prevention of Motion Sickness	Allot	Naval Medical Research Unit - Dayton : Dayton, OH	1.183	0.088	Oct 2014	0.300	Oct 2015	0.305	Oct 2016	-		0.305	Continuing	Continuing	Continuing
Validation of Color Vision Test for Naval Aviation	Allot	Naval Medical Research Unit - Dayton : Dayton, OH	0.788	0.072	Jan 2015	0.000		0.000		-		0.000	0.860	1.720	-
Validation of Mobile EEG Systems	Allot	Naval Health Research Center : San Diego, CA	0.426	0.349	Oct 2014	0.285	Oct 2015	0.000		-		0.000	0.106	1.166	-
Sustainable Team Performance	Allot	Naval Submarine Medical Research Laboratory : Groton, CT	0.401	0.364	Dec 2014	0.000		0.000		-		0.000	0.765	1.530	-
Medical Product Development	Various	Various : Not Specified	5.586	0.145	Sep 2015	1.636	Aug 2016	2.224	Aug 2017	-		2.224	Continuing	Continuing	Continuing
Subtotal			16.528	7.700		8.491		8.270		-		8.270	-	-	-

Management Services (\$ in Millions)				FY 2015		FY 2016		FY 2017 Base		FY 2017 OCO		FY 2017 Total	Cost To Complete	Total Cost	Target Value of Contract
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost			
Program Support	Various	Various : Not Specified	0.356	0.389	Aug 2015	0.800	Aug 2016	0.950	Aug 2017	-		0.950	Continuing	Continuing	Continuing
Subtotal			0.356	0.389		0.800		0.950		-		0.950	-	-	-

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2017 Navy **Date:** February 2016

Appropriation/Budget Activity 1319 / 5	R-1 Program Element (Number/Name) PE 0604771N / Medical Development	Project (Number/Name) 0933 / Medical/Dental Equipment Dev
--	---	---

Exhibit R-4, RDT&E Program Schedule Profile					Date: FEBRUARY 2016		
Appropriation/Budget Activity: BA5		Program Element Number and Name: 0604771N Medical Development			Project Number and Name: 0933 Medical and Dental Equipment Development		
Fiscal Year	FY15	FY16	FY17	FY18	FY19	FY20	FY21
Preventive Medicine: Malaria Vaccine (partner leveraged)							
Human Performance: Individualized Fatigue Based Scheduling and Countermeasure System							
Patient Movement/Casualty Management: MOVES SLC							
Patient Movement/Casualty Management: NEHSS shore based and afloat CBMTF							
Force Health Protection Future Capability Program Transition Products							

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2017 Navy **Date:** February 2016

Appropriation/Budget Activity 1319 / 5	R-1 Program Element (Number/Name) PE 0604771N / <i>Medical Development</i>	Project (Number/Name) 0933 / <i>Medical/Dental Equipment Dev</i>
--	--	--

Schedule Details

Events by Sub Project	Start		End	
	Quarter	Year	Quarter	Year
Proj 0933				
Preventive Medicine: Malaria Vaccine (Partner Leveraged): System Development	1	2015	1	2016
Preventive Medicine: Malaria Vaccine (Partner Leveraged): Validation of manufacturing scale up	4	2015	3	2017
Preventive Medicine: Malaria Vaccine (Partner Leveraged): Large Scale Efficacy/ Safety Trials	1	2017	4	2018
Preventive Medicine: Malaria Vaccine (Partner Leveraged): FDA Biological License Application	1	2019	4	2019
Human Performance: Individualized Fatigue Based Scheduling and Countermeasure System (IFBCS): Knowledge Transfer of Scheduling Component Complete	1	2015	3	2016
Human Performance: Individualized Fatigue Based Scheduling and Countermeasure System (IFBCS): Field Study Validation	1	2016	4	2018
Patient Movement/Casualty Management: Mobile Oxygen, Ventilation, and External Suction (MOVES) System: Ruggedized Design and Fabrication	1	2015	4	2015
Patient Movement/Casualty Management: Mobile Oxygen, Ventilation, and External Suction (MOVES) System: Ruggedized Evaluation	4	2015	4	2016
Patient Movement/Casualty Management: Naval Expeditionary Support Services shore based and afloat Capabilities Based MTF (NEHSS CB MTF): System Development	1	2015	1	2017
Patient Movement/Casualty Management: Naval Expeditionary Support Services shore based and afloat Capabilities Based MTF (NEHSS CB MTF): System Readiness Review	4	2016	1	2017
Patient Movement/Casualty Management: Naval Expeditionary Support Services shore based and afloat Capabilities Based MTF (NEHSS CB MTF): Technology Readiness Assessment	2	2020	3	2020

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2017 Navy **Date:** February 2016

Appropriation/Budget Activity 1319 / 5	R-1 Program Element (Number/Name) PE 0604771N / <i>Medical Development</i>	Project (Number/Name) 0933 / <i>Medical/Dental Equipment Dev</i>
--	--	--

Events by Sub Project	Start		End	
	Quarter	Year	Quarter	Year
Patient Movement/Casualty Management: Naval Expeditionary Support Services shore based and afloat Capabilities Based MTF (NEHSS CB MTF): Technology Readiness Review	1	2021	2	2021
Patient Movement/Casualty Management: Naval Expeditionary Support Services shore based and afloat Capabilities Based MTF (NEHSS CB MTF): Source selection and evaluation plan for pre-production	3	2021	4	2021
Force Health Protection Future Capability Program Transition Products: System Development	1	2015	2	2017
Force Health Protection Future Capability Program Transition Products: FDA Package Review Cerebral Perfusion Pressure Management	1	2017	3	2017

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2017 Navy **Date:** February 2016

Appropriation/Budget Activity 1319 / 5					R-1 Program Element (Number/Name) PE 0604771N / Medical Development				Project (Number/Name) 9999 / Congressional Adds			
COST (\$ in Millions)	Prior Years	FY 2015	FY 2016	FY 2017 Base	FY 2017 OCO	FY 2017 Total	FY 2018	FY 2019	FY 2020	FY 2021	Cost To Complete	Total Cost
9999: Congressional Adds	82.776	18.500	16.000	0.000	-	0.000	0.000	0.000	0.000	0.000	0.000	117.276
Quantity of RDT&E Articles		-	-	-	-	-	-	-	-	-		

Note

None

A. Mission Description and Budget Item Justification

Congressional Adds

B. Accomplishments/Planned Programs (\$ in Millions)

	FY 2015	FY 2016
Congressional Add: Military Dental Research	5.895	6.000
FY 2015 Accomplishments: Continue efforts in cranio-facial injury surveillance; combat dentistry; treatment of maxillofacial injury; dental disease non-battle injuries; oral/facial disease and infection in military personnel.		
FY 2016 Plans: N/A		
Congressional Add: Wound Care Research (transferred from Defense Health Program)	12.605	10.000
FY 2015 Accomplishments: Continue to develop novel diagnostics and treatments to enhance the care of the wounded warfighter.		
FY 2016 Plans: N/A		
Congressional Adds Subtotals	18.500	16.000

C. Other Program Funding Summary (\$ in Millions)

N/A

Remarks

D. Acquisition Strategy

None

E. Performance Metrics

Not required for Congressional adds.

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2017 Navy **Date:** February 2016

Appropriation/Budget Activity 1319 / 5	R-1 Program Element (Number/Name) PE 0604771N / <i>Medical Development</i>	Project (Number/Name) 9999 / <i>Congressional Adds</i>
--	--	--

FY 2015				FY 2016				FY 2017				FY 2018				FY 2019				FY 2020				FY 2021			
1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4

Proj 9999	
Military Dental Research: Schedule Detail	[REDACTED]
Wound Care Research: Schedule Detail	[REDACTED]

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2017 Navy **Date:** February 2016

Appropriation/Budget Activity 1319 / 5	R-1 Program Element (Number/Name) PE 0604771N / <i>Medical Development</i>	Project (Number/Name) 9999 / <i>Congressional Adds</i>
--	--	--

Schedule Details

Events by Sub Project	Start		End	
	Quarter	Year	Quarter	Year
Proj 9999				
Military Dental Research: Schedule Detail	4	2015	4	2016
Wound Care Research: Schedule Detail	4	2015	4	2016